立即開始
Ligand Pharmaceuticals Incorporated
看多

LGND is at the bottom of its range earnings reoprt 2/16/22

由djh860提供
they last reported sales were up 59% and profits were FAT because most of their revenues are from royalties so cost of sales is near zero.
This looks like a reasonable spot to buy in front of earnings.
earningswhispers.com/epsdetails/lgnd
Trend Analysis
djh860

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。